Compare ACADIA Pharmaceuticals Inc. (ACAD) vs CAVA Group Inc (CAVA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs CAVA Group Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.72 (market cap $4.49B), while CAVA Group Inc trades at $66.66 (market cap $8.12B). The key difference: CAVA Group Inc is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, CAVA Group Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | CAVA | |
|---|---|---|
Market Cap | $4.49B | $8.12B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $97.39 |
52-Week Low | $20.06 | $43.59 |
Enterprise Value | $3.69B | $8.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
CAVA stock is trading at $71.91, down 6.46% with a bearish technical signal. The company shows strong revenue growth reaching $1.18 billion in 2025 with positive net income of $63.74 million, though valuation metrics remain elevated with a P/E of 138.29. Recent earnings beat expectations in Q1 2026 with $0.20 EPS versus $0.17 expected. Analyst sentiment remains strongly positive with 72% buy ratings and a $94.19 consensus price target, representing 31% upside potential from current levels.
The outlook remains favorable given CAVA's expansion trajectory and market share gains in the fast-casual segment, though high valuation multiples and margin pressures present risks. The stock's recent pullback offers potential entry point for growth investors, but requires monitoring of same-store sales trends and competitive dynamics in the restaurant industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About CAVA Group Inc
CAVA is a Mediterranean fast-casual restaurant brand in the US. It offers customizable bowls, salads, and pitas featuring healthy ingredients, while also selling its signature dips and dressings in grocery stores.
Read more on CAVA →
